The study models two alternative downstream processes using magnetic separation to assess their economic feasibility compared to traditional monoclonal antibody (mAb) manufacturing. Integrating cell removal and product capture into a single operation enhances productivity, leading to significant cost savings and increased facility output. Predicted savings include a 38% reduction in cost of goods, a 17% decrease in capital investment, and a 40% increase in annual facility output. This approach offers a valuable option for mAb manufacturing by reducing process time and accommodating higher demands.

See the full article here